Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

ICC-1132, a recombinant virus-like particle comprising of a modified hepatitis B core protein with a B cell (NANP) and two T cell epitopes of Plasmodium falciparum circumsporozoite protein (CSP), was administered i.m. as a single 50 microg dose in Seppic ISA 720 to 11 volunteers. Local reactogenicity and systemic side effects were acceptable with the predominant finding being mild pain at the injection site. This regimen induced anti-NANP antibodies in 10/11 and modest T cell responses. There was no evidence of protection from experimental challenge with P. falciparum sporozoites. Other formulations and/or multi-dose regimens will be required to enhance the immunogenicity and efficacy of ICC-1132.

Original publication

DOI

10.1016/j.vaccine.2004.08.020

Type

Journal article

Journal

Vaccine

Publication Date

04/01/2005

Volume

23

Pages

857 - 864

Keywords

Adult, Amino Acid Sequence, Animals, Epitopes, T-Lymphocyte, Erythrocytes, Female, Hepatitis B virus, Humans, Malaria Vaccines, Malaria, Falciparum, Male, Plasmodium falciparum, Sporozoites